Breaking News
February 25, 2018 - New staining method helps analyze 3D tissue samples using Nano-CT system
February 25, 2018 - Rare immune cell may prove to be potent weapon in fighting against cancer
February 25, 2018 - Connection between heart disease and cancer treatment
February 25, 2018 - Longer Endocrine Tx Better in Prostate Cancer
February 25, 2018 - Gene therapy restores normal blood glucose levels in mice with type 1 diabetes
February 25, 2018 - Desymmetrization paves way for new bioactive compounds
February 25, 2018 - Study finds underutilization of less expensive, post-acute care options for older adults
February 25, 2018 - UNIST researchers introduce new biosensing contact lens for diabetics
February 25, 2018 - Research consortium develops first 3D computer model of metabolic processes
February 25, 2018 - Adding hope to health messages may help promote preventative actions, researchers say
February 25, 2018 - Sudden Hearing Loss Recovery Hampered by Metabolic Syndrome
February 25, 2018 - First human trial of potentially game-changing diabetes treatment set to commence
February 25, 2018 - Child’s snacking patterns could be linked to genetics, study finds
February 25, 2018 - Patients with terminal cancer may be less competent to make big decisions
February 25, 2018 - Study highlights risks involved in short-term use of PICCs
February 25, 2018 - Study shows no increase in complications with ‘ad lib’ oral intake during labor
February 25, 2018 - Although Plaquenil (Hydroxychloroquine) Eases Rheumatoid Arthritis Pain it Won’t Help ‘Regular’ Arthritis
February 25, 2018 - Methotrexate May Help in Chronic Viral Arthritis
February 25, 2018 - Lack of guidance may delay a child’s first trip to the dentist
February 25, 2018 - Study shows cost-effectiveness of screening for fracture risk in older postmenopausal women
February 24, 2018 - Younger women with SCAD may benefit most from conservative treatment
February 24, 2018 - Blood Test for Concussion OK’d
February 24, 2018 - What are symptoms of an alcohol use disorder? – Rethinking Drinking
February 24, 2018 - Streamlined, cost-cutting post-treatment dental advice via iPad
February 24, 2018 - Researchers discover new regulator of the immune system
February 24, 2018 - Reducing red tape for traveling nurses
February 24, 2018 - Study supports benefits of meditation in control of attention and emotions
February 24, 2018 - Flu Vax Data ‘Only Tell Half the Story’
February 24, 2018 - Calculators – Rethinking Drinking – NIAAA
February 24, 2018 - From stem cells to a functional heart—the role of the Mesp1 gene
February 24, 2018 - Non-adherence to sleep apnea treatment linked to increased hospital readmissions
February 24, 2018 - Exercise-related posts influence health of social media pals
February 24, 2018 - Will Device Meetings in Europe Suffer Under New Ethics Rule?
February 24, 2018 - Nonstatin drug use increases by 124% in U.S., related expenditures triple
February 24, 2018 - Annual foot screening could help spot heart irregularities in people with diabetes
February 24, 2018 - Researchers developing rapid saliva test to detect Zika virus
February 24, 2018 - For Older Men, Even Light Exercise Helps
February 24, 2018 - Healthy Strategies to Beat Stress
February 24, 2018 - Cancer killing clue could lead to safer and more powerful immunotherapies
February 24, 2018 - Repeated sick days do not affect children’s learning ability, study shows
February 24, 2018 - New two-child policy in China could negatively affect women’s status and gender equality
February 24, 2018 - New research project to determine why mine dust-related lung diseases are on the rise
February 24, 2018 - A Tribute to Dr. Ray Lipicky: The Man Who Transformed Cardiology
February 24, 2018 - ClinicalTrials.gov: Child, Foster
February 24, 2018 - Study shows age doesn’t affect survival in patients with non-Hodgkin lymphoma after HCT
February 24, 2018 - Researchers explore how evolutionary processes guide pathways of cells
February 24, 2018 - Discovery may result in new medication to build stronger muscles in old age
February 24, 2018 - New study identifies possible target for treatment of dangerous allergic reactions
February 24, 2018 - Targeted vaccination can be successful in containing epidemic outbreaks
February 24, 2018 - Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine
February 24, 2018 - ‘The Best Deals of Any Payer’: What We Heard This Week
February 24, 2018 - Blood and urine tests developed to indicate autism in children
February 24, 2018 - New low-cost microfluidic device brings single-cell technology to bedside
February 24, 2018 - Covestro and Pittsburgh Penguins announce multi-year unique partnership
February 24, 2018 - Children from low-income areas have poor outcomes after heart surgery, study finds
February 24, 2018 - Some genes can drive both metastasis and initial stages of tumor growth
February 24, 2018 - Visaris Americas announces installation of fully robotic Vision C digital X-ray suite at OGHS
February 24, 2018 - New discovery could accelerate clinical translation of stem cell-based therapies
February 24, 2018 - Respiratory disease patients with arthritis struggle to use complex inhalers
February 24, 2018 - FDA Alert: Labetalol Hydrochloride Injection by Hospira: Recall
February 24, 2018 - Flu, Tdap Vax Safe for Babies 6 Months Later
February 24, 2018 - Adults with autism show a diminished brain response to hearing their own name
February 24, 2018 - Study provides insight into neurobiology of dying
February 24, 2018 - Study finds tobacco smoke exposure among most adolescents in economically disadvantaged population
February 24, 2018 - U.S. clinical sites evaluating antibody-based therapies to prevent two common bacterial infections
February 24, 2018 - UCLA researchers use fluorescent colored proteins to trace origin of heart cells
February 24, 2018 - UC Riverside researchers discover way to halt cancer metastasis
February 24, 2018 - Home Routines Can Boost a Child’s Readiness for School
February 24, 2018 - FDA Investigating Misuse, Abuse of Gabapentinoids
February 24, 2018 - Scientists find key proteins control risk of osteoarthritis during aging
February 24, 2018 - Izon announce the launch of the qEV2 and qEV10 Exosome Isolation columns
February 24, 2018 - New CSIRO technology can create clean drinking water
February 24, 2018 - Treating sleep-disordered breathing may improve prognosis of heart failure patients
February 24, 2018 - More boys begin school a year late than girls, study finds
February 24, 2018 - Early life exposure to green space could have beneficial effects on cognitive function
February 24, 2018 - Joint Surgery: Aspirin Equals NOAC for Post-Acute VTE Prevention
February 23, 2018 - Scientists identify new marker of arthritis in mice
February 23, 2018 - Beetroot juice supplements may benefit patients with heart failure
February 23, 2018 - New study identifies novel molecular biomarkers of preeclampsia
February 23, 2018 - Researchers discover new link between gut bacteria and obesity
New report calls into question effectiveness of pregnancy anti-nausea drug

New report calls into question effectiveness of pregnancy anti-nausea drug

image_pdfDownload PDFimage_print
Previously unpublished information from the clinical trial that the US Food and Drug Administration relied on to approve the most commonly prescribed medicine for nausea in pregnancy indicates the drug is not effective, according to a new report by Dr. Nav Persaud, a researcher and family physician at St. Michael’s Hospital in Toronto. Credit: St. Michael’s Hospital

Previously unpublished information from the clinical trial that the U.S. Food and Drug Administration relied on to approve the most commonly prescribed medicine for nausea in pregnancy indicates the drug is not effective, a new report says.

Researchers at St. Michael’s Hospital obtained thousands of pages of documents from Health Canada relating to the randomized clinical trial that was reported in 2010 as showing pyridoxine-doxylamine was effective in reducing nausea and vomiting in pregnancy.

The trial found that on a 13-point scale, women who took the drug sold as Diclectin in Canada (Diclegis in the United States) reported symptom reductions that were 0.7 points greater than women who took a placebo.

But Dr. Nav Persaud, a researcher and family physician at St. Michael’s, said the manufacturer’s detailed 9,000-page “clinical study report” he obtained from Health Canada specified that the findings would be clinically important only if there were a three-point reduction in symptoms.

“That information was hidden until now,” he said.

His analysis was published today in the online journal PLOS ONE.

Dr. Persaud said that while the findings reported in 2010 may be statistically significant, they were not large enough to be noticeable by women taking the medication. By the end of the two-week trial, most women given a placebo had little or no symptoms.

Dr. Persaud said there was also “selective reporting” of secondary outcomes in the 2010 publication that made Diclectin appear effective. The 2010 paper indicated apparent benefits of the drug such as a reduction in the time lost from employment due to nausea and vomiting. But the 2010 publication did not include outcomes where there was no difference between the two groups, such as time lost from household tasks or number of visits to health-care providers.

The clinical trial was sponsored by Duchesnay Inc., the manufacturer of the drug. It was conducted at six university medical centres in the United States. The published results were based on 101 women who took pyridoxine-doxylamine and a control group of 86 women; the original enrollment was higher, but many women dropped out during the trial.

Dr. Persaud said that when Duchesnay approached the FDA in the early 2000s to approve pyridoxine-doxylamine, the regulatory agency said it needed evidence from a clinical trial. The FDA approved the drug in 2013, after this trial was done, and it has been prescribed in 33 million women worldwide according to the company. There is at least one prescription filled for every two births in Canada.

In the 1980s, the drug was voluntarily withdrawn from the American market in the midst of legal claims about birth defects that were eventually rejected by courts. Recently, Kim Kardashian was censured by the FDA for inappropriately promoting the drug on social media.

Dr. Persaud said the FDA should revisit its decision, as should Health Canada and provinces that offer the drug through publicly funded prescription drug plans. Clinicians could stop prescribing it and pregnant women could seek effective treatments instead of this drug, he said.


Explore further:
Data on effectiveness of morning sickness drug may be flawed

Journal reference:
PLoS ONE

Provided by:
St. Michael’s Hospital

Tagged with:

About author

Related Articles